Onyda XR and newer non-stimulant ADHD approvals: state of practice

Why the non-stimulant class is worth attention

Stimulants (methylphenidate, amphetamine) are the first-line pharmacologic treatment for ADHD. They work in about 70 to 80 percent of patients, with effect sizes larger than any non-stimulant. There's no serious dispute about this in the guideline literature.

Non-stimulants exist because:

Some patients don't tolerate stimulants (appetite suppression, sleep disturbance, mood irritability, tics, blood pressure or heart rate concerns, anxiety exacerbation).

Some patients don't respond to stimulants adequately, even after methylphenidate and amphetamine trials with dose optimization.

Some families or patients prefer a non-controlled substance for legitimate reasons including SUD history, storage concerns with other children in the home, or philosophical preference.

Some clinical situations argue against stimulants: severe comorbid anxiety where activation is a concern, active tics where stimulants may unmask or worsen them (this is complicated in the literature but real in some patients), significant cardiovascular disease, uncontrolled hypertension.

For all of these, non-stimulants have been the alternative. Historically that meant atomoxetine (approved 2002), and later guanfacine ER (2009) and clonidine ER (2010). The two newer additions to the class are Qelbree (viloxazine ER) in 2021-22 and Onyda XR (extended-release liquid clonidine) in 2024.

Onyda XR: what it is and why it exists

Onyda XR is extended-release liquid clonidine, approved for ADHD in ages 6 to 17. The mechanism is the same as tablet extended-release clonidine (Kapvay): central alpha-2 adrenergic agonism, which likely modulates prefrontal cortex noradrenergic tone in a way that supports attention and impulse regulation.

Why liquid extended-release matters practically: many young pediatric patients cannot swallow tablets, and the workarounds (crushing tablets, mixing with food) either aren't clinically appropriate (crushing an extended-release tablet destroys the ER kinetics) or aren't reliable (mixing with food changes absorption). Before Onyda XR, the choice for young kids was either immediate-release clonidine given multiple times daily (adherence problem, blood pressure fluctuation) or non-clonidine alternatives. Onyda XR fills a specific gap for young pediatric patients where liquid dosing is what makes treatment possible.

Onyda XR dosing: 0.1 mg once daily starting dose, titrated up weekly in 0.1 mg increments to a maximum of 0.4 mg once daily. Dosing is at bedtime because sedation is dose-limiting. Weight-based considerations apply for smaller children but the label doesn't require formal weight-based dosing.

Adverse events are consistent with clonidine class: somnolence (the dose-limiting side effect), fatigue, dry mouth, hypotension, orthostatic dizziness. Rebound hypertension on abrupt discontinuation is a real risk and the label warns against stopping without taper. In practice, tapering by 0.1 mg every 3 to 7 days is safe. Bradycardia and hypotension warrant baseline and periodic blood pressure and heart rate monitoring.

The efficacy signal in the pediatric ADHD trials was modest, similar to other non-stimulants: statistically significant improvement over placebo on ADHD-RS-IV total score, with effect sizes smaller than what stimulants produce. That's the class trade-off.

Qelbree (viloxazine ER): what it is

Qelbree is extended-release viloxazine, a norepinephrine reuptake inhibitor with some serotonergic activity through 5-HT2B antagonism and 5-HT2C agonism. Viloxazine itself was used in Europe as an antidepressant in the 1980s and later discontinued. The extended-release formulation and the ADHD reformulation is a genuinely new drug in the US, and it's the first new non-stimulant mechanism approved for ADHD in over a decade.

Qelbree got pediatric ADHD approval in April 2021 and adult ADHD approval in April 2022. The dosing is 200 mg once daily starting dose for pediatrics 6 to 17 (with weekly titration to 400 mg or 600 mg based on response and tolerability), and 200 mg once daily starting dose for adults (with titration to 400 mg or 600 mg).

Qelbree is metabolized primarily by CYP2D6 and CYP2C19, and it's a strong CYP1A2 inhibitor. That last point is important because caffeine, tizanidine, olanzapine, and clozapine are all CYP1A2 substrates, and combining Qelbree with them can raise their levels significantly. This is a real interaction and worth being explicit about.

Qelbree's adverse event profile in the trials: somnolence (about 15 to 20 percent), fatigue, decreased appetite, headache, insomnia (yes, in some patients despite the somnolence signal in others), nausea. Discontinuation for adverse events ran around 5 percent in trials. Blood pressure and heart rate elevations were modest but real and warrant monitoring.

Suicidal ideation warning: Qelbree carries a boxed warning about suicidal ideation, particularly in pediatric patients, similar to other antidepressant-related compounds. This has affected some prescribers' willingness to start it, especially in patients with depression or suicidality history. In the trials, the incidence of suicidal ideation events was small but statistically detectable versus placebo, and the label reflects that.

Efficacy in the pivotal trials was similar to atomoxetine: about a 5-point improvement on ADHD-RS-5 versus placebo at week 6 in pediatrics, with adult effect sizes similar. Not stimulant-level, but a genuine non-stimulant option with a different mechanism than atomoxetine.

Where these newer non-stimulants fit right now

Onyda XR is a genuine addition for one specific population: young pediatric patients (typically 6 to 8) who cannot swallow tablets, where extended-release clonidine is otherwise a good clinical choice (comorbid tics, sleep problems, anxiety with stimulants, family preference for non-controlled substance). Before Onyda XR, this meant multi-times-daily immediate-release clonidine, and Onyda XR is the first ER liquid option. For older pediatric patients and adults, generic extended-release clonidine tablets remain a cheaper option with equivalent efficacy.

Qelbree is a genuine addition for pediatric and adult patients where atomoxetine hasn't worked, hasn't been tolerated, or where an SNRI-adjacent mechanism might work through a different receptor pattern. It's also useful where the CYP2D6 pharmacogenetics make atomoxetine dosing hard (atomoxetine poor metabolizers get high levels and more side effects at standard doses). Qelbree has its own CYP interactions but the CYP2D6 issue is less limiting.

The broader non-stimulant landscape in mid-2026:

Atomoxetine (Strattera, generic): still the workhorse non-stimulant. Twice-daily or once-daily dosing, no controlled substance schedule, decent evidence base, and generic. Weeks-to-work timeline (4 to 8 weeks for full effect), which some families find unacceptable. Cost is low.

Guanfacine ER (Intuniv, generic): alpha-2A agonist, once-daily, less sedating than clonidine but still causes fatigue and orthostasis. Often chosen for patients where anxiety or sleep issues are prominent. Generic available and cheap.

Clonidine ER (Kapvay, generic): alpha-2 agonist, twice-daily dosing, more sedating than guanfacine. Good option for patients with tics, insomnia, or hyperactivity-predominant presentation.

Onyda XR: once-daily liquid extended-release clonidine, adds the liquid formulation option specifically.

Qelbree (viloxazine ER): SNRI-adjacent mechanism with some serotonergic activity. Once-daily dosing.

Common questions

Should I try a non-stimulant before a stimulant? In most patients, no. Stimulants are more effective on average, better tolerated in many patients, and have a faster time-to-effect. Guidelines from AAP, AACAP, and adult ADHD organizations recommend stimulants as first-line unless there's a specific contraindication or preference. Non-stimulants are typically second-line after stimulant failure or intolerance.

Which non-stimulant should I choose? Depends on the reason for choosing non-stimulant.

If comorbid tics: guanfacine ER or clonidine ER (including Onyda XR if liquid needed) are often first-choice among non-stimulants because they may improve tics.

If comorbid anxiety: guanfacine ER is often preferred over Qelbree because Qelbree's activating potential is real for some patients.

If comorbid sleep problems: clonidine ER (including Onyda XR) is often preferred, dosed at bedtime, because sedation is often welcome.

If patient wants a once-daily oral tablet with a mechanism unlike atomoxetine: Qelbree.

If cost is dominant: generic atomoxetine, generic guanfacine ER, or generic clonidine ER.

Can non-stimulants be combined with stimulants? Yes, and this is common. A stimulant plus low-dose guanfacine or clonidine is a well-established augmentation strategy for patients who partially respond to stimulants but have residual symptoms (especially evening or off-medication window symptoms, or tics that emerge on stimulant). Atomoxetine plus stimulant is used less often but has evidence. Qelbree plus stimulant is theoretically possible but underevaluated in trials.

How long until non-stimulants work? Longer than stimulants. Atomoxetine takes 4 to 8 weeks. Qelbree takes 2 to 4 weeks. Guanfacine ER and clonidine ER show effects in 1 to 2 weeks but full effect at 4 to 6 weeks. Onyda XR is similar to other clonidine ER.

What monitoring is needed? Blood pressure and heart rate at baseline and periodically during titration for all non-stimulants. Weight for kids on Qelbree. Suicidal ideation screening for Qelbree pediatric patients. Standard growth monitoring for all pediatric ADHD drugs.

What about SUD history? Non-stimulants are often preferred over stimulants for patients with SUD history, particularly stimulant use disorder or cocaine use disorder. Atomoxetine is the most studied in SUD populations and has a reasonable evidence base for use during recovery. Qelbree is newer and less studied in SUD but doesn't have obvious concerns. Guanfacine and clonidine are also used.

What's the relationship between non-stimulants and stimulant abuse potential? None of the non-stimulants (atomoxetine, guanfacine, clonidine including Onyda XR, or Qelbree) are DEA scheduled. None have documented abuse liability. This is a major practical advantage for patients or families where the controlled substance handling of stimulants is a real barrier (recovery homes, group homes, some school policies).

Are non-stimulants effective for adult ADHD? Yes, though the effect sizes remain smaller than stimulants. Atomoxetine and Qelbree both have adult indications. Guanfacine ER has evidence in adults but is not FDA-approved for adult ADHD specifically. Clonidine ER (including Onyda XR) is approved only for pediatric ADHD.

What's next

The next non-stimulant in development is centanafadine (BAP0090), a triple reuptake inhibitor of norepinephrine, dopamine, and serotonin. Otsuka has run Phase 3 trials with mixed results, and the FDA path is unclear as of mid-2026. If approved, it would be the first non-stimulant with dopaminergic activity in its mechanism.

The other trend to watch is atomoxetine dose optimization by CYP2D6 genotype. Pretreatment CYP2D6 genotyping is not yet standard, but for patients failing standard atomoxetine dosing or having side effects at low doses, genotype-informed dosing improves outcomes. Whether this becomes standard practice depends on cost and workflow, but the evidence base is strengthening.

For prescribing psychiatry, the practical implication of the newer non-stimulants is a slightly wider menu when stimulants aren't the right choice. Onyda XR solves a specific pediatric liquid-formulation gap. Qelbree adds a mechanism option beyond atomoxetine. Neither transforms ADHD treatment. Both give more patients a workable non-stimulant option.

Sources

• Onyda XR (clonidine extended-release oral suspension). Prescribing information. Tris Pharma; approved May 2024. Available via DailyMed.
• Qelbree (viloxazine extended-release capsules). Prescribing information. Supernus Pharmaceuticals; pediatric approval April 2021, adult approval April 2022.
• Nagy CF, Anderson C, Adler LA, et al. Efficacy and safety of viloxazine ER in the treatment of adults with ADHD: a randomized clinical trial. J Clin Psychiatry. 2022.
• Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009.
• Wolraich ML, Hagan JF, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019;144(4):e20192528. (AAP guideline)
• Faraone SV, Rostain AL, Blader J, et al. Practitioner review: ADHD in adults. J Child Psychol Psychiatry. 2019.